Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy.
MRI
NLR
PNI
biopsy
dNLR
prostate cancer
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
19 Nov 2021
19 Nov 2021
Historique:
received:
07
10
2021
revised:
13
11
2021
accepted:
16
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
The aim of this study was to assess the predictive value of pre-biopsy blood-based markers in patients undergoing a fusion biopsy for suspicious prostate magnetic resonance imaging (MRI). We identified 365 consecutive patients who underwent MRI-targeted and systematic prostate biopsy for an MRI scored Prostate Imaging-Reporting and Data System Version (PI-RADS) ≥ 3. We evaluated the neutrophil/lymphocyte ratio (NLR), derived neutrophil/lymphocyte ratio (dNLR), platelet/lymphocyte ratio (PLR), systemic immune inflammation index (SII), lymphocyte/monocyte ratio (LMR,) de Ritis ratio, modified Glasgow Prognostic Score (mGPS), and prognostic nutrition index (PNI). Uni- and multivariable logistic models were used to analyze the association of the biomarkers with biopsy findings. The clinical benefits of biomarkers implemented in clinical decision-making were assessed using decision curve analysis (DCA). In total, 69% and 58% of patients were diagnosed with any prostate cancer and Gleason Grade (GG) ≥ 2, respectively. On multivariable analysis, only high dNLR (odds ratio (OR) 2.61, 95% confidence interval (CI) 1.23-5.56,
Identifiants
pubmed: 34834583
pii: jpm11111231
doi: 10.3390/jpm11111231
pmc: PMC8625876
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Diagnostics (Basel). 2021 Feb 20;11(2):
pubmed: 33672608
Minerva Urol Nephrol. 2021 Jun 11;:
pubmed: 34114784
Diagnostics (Basel). 2021 Feb 20;11(2):
pubmed: 33672650
BMC Cancer. 2020 Apr 29;20(1):361
pubmed: 32349713
Ann Oncol. 2015 Apr;26(4):743-749
pubmed: 25515657
Br J Cancer. 2017 Jan 3;116(1):85-90
pubmed: 27907929
Sci Rep. 2019 May 3;9(1):6870
pubmed: 31053749
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
Eur Urol. 2021 Nov;80(5):549-563
pubmed: 34020828
Int J Urol. 2021 Jan;28(1):47-52
pubmed: 32985040
Arch Med Sci. 2017 Sep 21;16(5):1062-1071
pubmed: 32863995
BJU Int. 2020 Apr;125(4):531-540
pubmed: 31762182
Urol Oncol. 2020 May;38(5):401-409
pubmed: 31870724
Abdom Radiol (NY). 2020 Dec;45(12):4031-4039
pubmed: 32232525
BJU Int. 2018 Jul;122(1):50-58
pubmed: 29388388
Cancers (Basel). 2021 Apr 23;13(9):
pubmed: 33922626
World J Surg. 2013 Nov;37(11):2688-92
pubmed: 23884382
Eur Urol. 2014 Sep;66(3):430-6
pubmed: 24377803
Radiology. 2021 Aug;300(2):369-379
pubmed: 34032510
Urol Oncol. 2021 Nov;39(11):785.e19-785.e27
pubmed: 34116934
Urol Oncol. 2020 Dec;38(12):936.e7-936.e14
pubmed: 32962909
J Magn Reson Imaging. 2021 Jul 5;:
pubmed: 34227169
N Engl J Med. 2020 Mar 5;382(10):917-928
pubmed: 32130814
Cancer Res. 2009 Jul 1;69(13):5383-91
pubmed: 19549917
Eur Urol. 2019 Mar;75(3):385-396
pubmed: 29908876
Cancer Res Treat. 2018 Apr;50(2):356-365
pubmed: 28546520
Urol Oncol. 2020 Jul;38(7):623-635
pubmed: 32284256
J Urol. 2017 Sep;198(3):575-582
pubmed: 28373135
Eur Urol. 2013 Dec;64(6):876-92
pubmed: 23787356
J Urol. 2020 Dec;204(6):1141-1149
pubmed: 32716687
JAMA Oncol. 2021 Apr 1;7(4):534-542
pubmed: 33538782
Urol Int. 2019;102(1):43-50
pubmed: 30408799
Cancer. 2004 Jun 1;100(11):2281-91
pubmed: 15160330
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Eur Urol. 2020 Mar;77(3):311-317
pubmed: 31708295
Eur Urol Oncol. 2020 Oct;3(5):700-704
pubmed: 31548130
Prostate. 2017 Sep;77(12):1233-1241
pubmed: 28752926
Prostate. 2017 Oct;77(14):1401-1407
pubmed: 28853167
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249